NasdaqGS:TARSPharmaceuticals
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial
Tarsus Pharmaceuticals has already dosed the first participant in its Phase 2 Calliope trial of TP-05, an oral lotilaner-based therapy being tested in about 700 at-risk adults across U.S. Lyme-endemic regions, where no FDA-approved drug prophylaxis currently exists.
This move extends Tarsus beyond eye-care into infectious disease prevention, targeting a large U.S. population considered at moderate to high risk for Lyme disease.
We’ll now examine how TP-05’s Phase 2 progress, as a potential...